Amendments to the Specification

Please replace the paragraph [0037] of the application as published (US2007/0202103) with the following amended paragraph:

> In a preferred embodiment, the compound of the first aspect of the invention comprises a target specific portion comprising a ~~human~~ humanized BC1 heavy chain variable region of SEQ ID NO: 1.

Please replace the paragraph [0038] of the application as published (US2007/0202103) with the following amended paragraph:

> Advantageously, the compound of the first aspect of the invention comprises a target specific portion comprising a ~~human~~ humanized BC1 light chain variable region of EQ ID NO: 2.

Please replace the paragraph [0039] of the application as published (US2007/0202103) with the following amended paragraph:

> Conveniently, the compound of the first aspect of the invention comprises a target specific portion comprising a ~~human~~ humanized BC1 heavy chain variable region of SEQ ID NO: 1 and a ~~human~~ humanized BC1 light chain variable region of SEQ ID NO: 2.

Please replace the paragraph [0165] of the application as published (US2007/0202103) with the following amended paragraph:

> Surface plasmon resonance (SPR) technology was used to demonstrate specificity of antigen binding (i.e. recognition of only the recombinant oncofoetal ibronectin, FN7B 89) and to determine/compare the kinetic rate constants/affinity values for both murine and ~~human~~ humanized BC1 antibodies and BC1-IL12 Immunocytokines. All measurements reagents and software provided by Biocore ~~(see appendix for list of reagents and software)~~.

Please replace the paragraph [0167] of the application as published (US2007/0202103) with the following amended paragraph:

> For kinetic analysis, only the ED-B positive fibronectin (FN7B89) was coupled to the chip. Three difference densities were coupled on three different flow cells.

The fourth flow cell was left uncoupled and used as a negative control. Four to five concentrations of each molecule were prepared by performing twofold serial dilutions ranging from 1000 nM to 125 nM (muBC1), 200 nM to 25 nM (huBC1) and 100 nM to 6.25 nM (murine and ~~human~~ humanized BC1-IL12). The serial dilutions were made in triplicate in the running buffer (HBS-EP). Each dilution was injected for 5 min (association) followed by 5 min of running buffer (dissociation) at a flow rate of 10 TL/min. The flow cells were regenerated as was done in the antigen specificity experiments described above. Curve fitting was done using software provided by Biacore. ~~See the appendix for specific details on curve fitting.~~